BioLife Q3 revenue $40.7M (+21% YoY); biopreservation media +50%; tightens FY22 guidance to $160-164M

BIOLIFE SOLUTIONS INC

2022-Q3 EPS reported -$2.11 revenue$117,500,000

GAAP net loss of $10.0M ($0.23 loss per share) vs net income of $79K in Q3 2021.
Adjusted EBITDA turned positive at $1.4M versus negative $2.1M in Q3 2021.
Cell Processing platform revenue $18.1M (+57% YoY); Freezer/Thaw Systems $15.3M (-13% YoY).
Cash, equivalents and marketable securities $62.1M; borrowed $20M via term loan in Q3.
FY2022 revenue guidance narrowed to $160-164M from $160-166M; organic growth expected 37-40%.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

BIOLIFE SOLUTIONS INC reported the three and nine months ended September 30, 2022 results: revenue Total revenue for the third quarter of 2022 was $40.7 million. Guidance reaffirmed.

Period: the three and nine months ended September 30, 2022
Revenue: Total revenue for the third quarter of 2022 was $40.7 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

On November 9, 2022, BioLife Solutions, Inc. issued a press release announcing financial results and operational highlights for the third quarter ended September 30, 2022.

View on SEC.gov

Browse all earnings releases →

BIOLIFE SOLUTIONS INC filing history →

Source: SEC EDGAR

accession 0001437749-22-026595

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.